Methadone based ERAS
Phase 3Small molecule
Methadone based ERAS is one of 4 small molecule programs targeting Spine Fusion. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Spine Fusion
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Rayos
RRoxane Laboratories
Approved
Ambien
SanofiPhase 3
Methadone based ERAS
SSenthil Sadhasivam
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methadone based ERAS. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSenthil Sadhasivam